SLC9A2 , suppressing by the transcription suppressor ETS1 , restrains growth and invasion of osteosarcoma via inhibition of aerobic glycolysis
Environmental Toxicology · 2024
DOI: 10.1002/tox.23963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology, 2024. Verfasst von Jiangbo Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, China. Hauptthemen laut MEDLINE: Osteosarcoma, MicroRNAs, Bone Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Recent studies have shown that Solute Carrier Family 9 Member A2 (SLC9A2) could serve as a biomarker for cancer. However, its mechanism of action in osteosarcoma (OS) was still unclear. In this study, the data sets GSE154530 and GSE99671 were downloaded from the Gene Expression Omnibus (GEO) database, and 31 differentially expressed genes (DEGs) related to methylation were screened by bioinformatics analysis tools. Subsequently, SLC9A2 was screened as a candidate gene from DEGs, which was significantly downregulated in OS. CCK‐8, transwell, western blotting and Seahorse XFe24 Cell Metabolic Analyzer assays demonstrated that overexpression of SLC9A2 could constrain OS cell proliferation, invasion, and aerobic glycolysis. Dual‐luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) assays indicated ETS proto‐oncogene 1 (ETS1) was a transcription suppressor of SLC9A2, and overexpression of ETS1 could promote methylation levels in specific regions of the SLC9A2 promoter. ETS1 could promote the proliferation, invasion, and aerobic glycolysis ability of OS cells, as well as tumor growth in vivo by inhibiting the expression of SLC9A2. In addition, SLC9A2, suppressing by ETS1, restrains growth and invasion of OS via inhibition of aerobic glycolysis. Thus, SLC9A2 can function as a key inhibitory factor in the aerobic glycolysis to inhibit proliferation and invasion of OS. This indicated that SLC9A2 has a potential targeted therapeutic effect on OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, China.
- Department of Orthopedics, Xi'an Chang'an District Hospital, Xi'an, China.
- Department of Anesthesiology, Xi'an Chang'an District Hospital, Xi'an, China.
ORCID-Profile: Weiguo Bian
Zitieren
APA
Han, J., Li, S., Cao, J., Han, H., Lu, B., Wen, T., & Bian, W. (2024). SLC9A2 , suppressing by the transcription suppressor ETS1 , restrains growth and invasion of osteosarcoma via inhibition of aerobic glycolysis. Environmental Toxicology. https://doi.org/10.1002/tox.23963
Vancouver
Han J, Li S, Cao J, Han H, Lu B, Wen T, et al. SLC9A2 , suppressing by the transcription suppressor ETS1 , restrains growth and invasion of osteosarcoma via inhibition of aerobic glycolysis. Environmental Toxicology. 2024. doi:10.1002/tox.23963
BibTeX
@article{Han2024,
author = {Han, Jiangbo and Li, Shen and Cao, Jiongzhe and Han, Hong and Lu, Bin and Wen, Tao and Bian, Weiguo},
title = {SLC9A2 , suppressing by the transcription suppressor ETS1 , restrains growth and invasion of osteosarcoma via inhibition of aerobic glycolysis},
journal = {Environmental Toxicology},
year = {2024},
doi = {10.1002/tox.23963}
}
EUVIMED